Screener
United Therapeutics UTHR Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by United Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromLinesOfCredit.
The source filing: United Therapeutics’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 6:31 AM EST
- Fiscal year
- FY2025
- Accession
- 0001082554-26-000006
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Net cash (used in) provided by investing activities | (551.3) | 417.2 | (719.6) |
| Cash flows from financing activities: | |||
| Payments to repurchase common stock | (1,000.0) | (1,000.0) | — |
| Proceeds from line of credit | 200.0 | — | — |
| Repayment of line of credit | (500.0) | (400.0) | (100.0) |
| Excise tax paid on net share repurchase | (5.0) | — | — |
| Payments of debt issuance costs | (11.5) | (2.7) | (2.7) |
| Proceeds from the exercise of stock options | 173.9 | 152.5 | 98.0 |
Item 8. Financial Statements and Supplementary DataF-
FAQ
- What is United Therapeutics's debt issuance proceeds?
- United Therapeutics (UTHR) reported debt issuance proceeds of $50M in Q4 2025.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about United Therapeutics's debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude